Systematic Analysis of Breast Cancer Morphology Uncovers Stromal Features Associated with Survival

Automated quantification of thousands of morphologic features in microscopic images of breast cancer allows the construction of a robust prognostic model. An Automated Pathologist Reads Cancer Biopsies How is a camera different from the human eye? Only the eye’s images undergo extensive secondary processing as they are interpreted by the human brain. But what if we could program a computer to do the secondary processing? A pathologist reading a cancer biopsy slide matches his or her brain’s memory of certain cancer-related features (tubules, atypical nuclei, and mitosis) against the tissue. This decades-old scoring system is still standard in most places for prognosis and treatment of cancer, despite its variability and often unreliability. Now, Beck et al. have created an automated pathologist by replacing the human brain with sophisticated image processing software and instructing it to find quantitative aspects of breast cancer tissue that predict prognosis. The software located a set of features that strongly predicted breast cancer outcome in both training and validation samples. With an image analysis protocol they termed C-Path, the authors set their program loose on a set of samples from patients in the Netherlands. From more than 6000 features, the software found a set that were associated with samples from patients who had died sooner. The key aspect of this analysis was that these features were not predefined by a pathologist as being relevant to cancer; instead, the software itself found the cancer-related features among the very large set of measurements of the image. Classifying the tissue as epithelial or stromal, an important part of cancer diagnosis, took a bit of extra work: The authors needed to provide the software with some hand-marked samples so it could learn the difference. The C-Path score yielded information above and beyond that from many other measures of cancer severity including pathology grade, estrogen receptor status, tumor size, and lymph node status. In another, completely independent group of women from Vancouver, the C-Path score was also associated with overall survival. An unexpected finding was that the features that were the best predictors of patient survival were not from the cancer itself but were from the adjacent stromal tissue. Women with worse outcomes tended to have thin cords of epithelial cells infiltrating the stroma, which resulted in high-risk stromal matrix variability scores. These patients also tended to have more inflammatory cells in the stroma (picked up as dark areas by the software). Replacing the human brain with an unbiased image processing system can extract more information from microcopy images and discover new biological aspects of cancer tissue. The morphological interpretation of histologic sections forms the basis of diagnosis and prognostication for cancer. In the diagnosis of carcinomas, pathologists perform a semiquantitative analysis of a small set of morphological features to determine the cancer’s histologic grade. Physicians use histologic grade to inform their assessment of a carcinoma’s aggressiveness and a patient’s prognosis. Nevertheless, the determination of grade in breast cancer examines only a small set of morphological features of breast cancer epithelial cells, which has been largely unchanged since the 1920s. A comprehensive analysis of automatically quantitated morphological features could identify characteristics of prognostic relevance and provide an accurate and reproducible means for assessing prognosis from microscopic image data. We developed the C-Path (Computational Pathologist) system to measure a rich quantitative feature set from the breast cancer epithelium and stroma (6642 features), including both standard morphometric descriptors of image objects and higher-level contextual, relational, and global image features. These measurements were used to construct a prognostic model. We applied the C-Path system to microscopic images from two independent cohorts of breast cancer patients [from the Netherlands Cancer Institute (NKI) cohort, n = 248, and the Vancouver General Hospital (VGH) cohort, n = 328]. The prognostic model score generated by our system was strongly associated with overall survival in both the NKI and the VGH cohorts (both log-rank P ≤ 0.001). This association was independent of clinical, pathological, and molecular factors. Three stromal features were significantly associated with survival, and this association was stronger than the association of survival with epithelial characteristics in the model. These findings implicate stromal morphologic structure as a previously unrecognized prognostic determinant for breast cancer.

[1]  F. Welch,et al.  Causes and Consequences , 2017, Nature.

[2]  R. W. Scarff,et al.  THE POSITION OF HISTOLOGY IN THE PROGNOSIS OF CARCINOMA OF THE BREAST. , 1928 .

[3]  H. Bloom,et al.  Histological Grading and Prognosis in Breast Cancer , 1957, British Journal of Cancer.

[4]  Causes and consequences , 2021 .

[5]  P. Fialkow Is lyonisation total in man? , 1970, Lancet.

[6]  J. Baak,et al.  MORPHOMETRY FOR PROGNOSIS PREDICTION IN BREAST CANCER , 1981, The Lancet.

[7]  S Friedman,et al.  Prognostic value of histologic grade nuclear components of Scarff‐Bloom‐Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas , 1989, Cancer.

[8]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[9]  Anthony C. Davison,et al.  Bootstrap Methods and Their Application , 1998 .

[10]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[11]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Mina J. Bissell,et al.  Putting tumours in context , 2001, Nature Reviews Cancer.

[13]  J. Baak,et al.  The framework of pathology: good laboratory practice by quantitative and molecular methods , 2002, The Journal of pathology.

[14]  Zena Werb,et al.  Stromal Effects on Mammary Gland Development and Breast Cancer , 2002, Science.

[15]  Yudong D. He,et al.  A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .

[16]  R. Tibshirani,et al.  Statistical Applications in Genetics and Molecular Biology Pre-validation and inference in microarrays , 2011 .

[17]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[18]  Tina Hernandez-Boussard,et al.  Determination of Stromal Signatures in Breast Carcinoma , 2005, PLoS biology.

[19]  G. Collins The next generation. , 2006, Scientific American.

[20]  M. J. van de Vijver,et al.  Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. , 2006, Journal of the National Cancer Institute.

[21]  Trevor Hastie,et al.  Gene Expression Programs in Response to Hypoxia: Cell Type Specificity and Prognostic Significance in Human Cancers , 2006, PLoS medicine.

[22]  C. Sotiriou,et al.  Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? , 2007, Nature Reviews Cancer.

[23]  G. Sherlock,et al.  The prognostic role of a gene signature from tumorigenic breast-cancer cells. , 2007, The New England journal of medicine.

[24]  Ross Tubo,et al.  Mesenchymal stem cells within tumour stroma promote breast cancer metastasis , 2007, Nature.

[25]  Mikhail Teverovskiy,et al.  Improved prediction of prostate cancer recurrence through systems pathology. , 2007, The Journal of clinical investigation.

[26]  C. Colpaert,et al.  A fibrotic focus is a prognostic factor and a surrogate marker for hypoxia and (lymph)angiogenesis in breast cancer: review of the literature and proposal on the criteria of evaluation , 2007, Histopathology.

[27]  Gerardo Fernandez,et al.  Systems pathology approach for the prediction of prostate cancer progression after radical prostatectomy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Rudolf Hanka,et al.  Assessing Agreement between Multiple Raters with Missing Rating Information, Applied to Breast Cancer Tumour Grading , 2008, PloS one.

[29]  Andrew H. Beck,et al.  The fibromatosis signature defines a robust stromal response in breast carcinoma , 2008, Laboratory Investigation.

[30]  Laoighse Mulrane,et al.  Automated image analysis in histopathology: a valuable tool in medical diagnostics , 2008, Expert review of molecular diagnostics.

[31]  T. Sørlie,et al.  Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome , 2008, The Journal of pathology.

[32]  Trevor Hastie,et al.  Combining biological gene expression signatures in predicting outcome in breast cancer: An alternative to supervised classification. , 2008, European journal of cancer.

[33]  F. Pépin,et al.  Stromal gene expression predicts clinical outcome in breast cancer , 2008, Nature Medicine.

[34]  Ryan D. Morin,et al.  Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution , 2009, Nature.

[35]  Yuan Qi,et al.  Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Trevor Hastie,et al.  Regularization Paths for Generalized Linear Models via Coordinate Descent. , 2010, Journal of statistical software.

[37]  Jorge S. Reis-Filho,et al.  Molecular Profiling: Moving Away from Tumor Philately , 2010, Science Translational Medicine.

[38]  K. Polyak,et al.  Tumor heterogeneity: causes and consequences. , 2010, Biochimica et biophysica acta.

[39]  Joshua F. McMichael,et al.  Genome Remodeling in a Basal-like Breast Cancer Metastasis and Xenograft , 2010, Nature.

[40]  C. Hitchcock,et al.  The future of telepathology for the developing world. , 2011, Archives of pathology & laboratory medicine.

[41]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[42]  J. Cheng,et al.  Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL–RANK signalling , 2011, Nature.